Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study

Nicola Conran, PhD, Kleber Yotsumoto Fertrin, MD PhD, Claudia de Alvarenga Maximo, MD, Thais Oliveira, B.Sc., Clarisse Lobo, MD PhD, Fernando Ferreira Costa, MD PhD

Blood (2019) 134 (Supplement_1): 2303.

https://doi.org/10.1182/blood-2019-130106

Published: 2019

Journal Articles

Initial Molecular Response At 3 Months Can Identify Three Groups Of Patients With Different Responses and Event-Free Survival At 36-Months Following Second-Generation Tyrosine Kinase Inhibitor Therapy In Imatinib-Resistant Chronic Myeloid Leukemia

Carla Boquimpani, MD, Rony Schaffel, MD, PhD, Daniel Graça, Camila Mesquita, Tania Silva Madeira, MD, Danielle Peixoto, MD, Patricia Wendling, MD, Clarisse Lobo, MD, Irene Biasoli, MD, PhD, Nelson Spector, MD, PhD

Blood (2013) 122 (21): 4005.

https://doi.org/10.1182/blood.V122.21.4005.4005

Published: 2013

Journal Articles

Cognitive Dysfunction Occurs In Children with Sickle Cell Anemia without Cerebral Ischemic Insult or Vasculopathy

Clarisse Lobo, MD, Patricia Moura, MD, Patricia Rio, Psych, Heber Maia, MD, PhD, MSc, Juliana Fernandes, Psych, Jorge Cunha Pinto, MD, Ana C Leite, MD, PhD, Jane S Hankins, MD, MS

Blood (2011) 118 (21): 1076.

https://doi.org/10.1182/blood.V118.21.1076.1076

Published: 2011

Journal Articles

Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID

Andreas Hochhaus, MD, Gert Ossenkoppele, MD, PhD, Josy Reiffers, MD, Ming Yao, MD, Hirohiko Shibayama, MD, PhD, Norbert Gattermann, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, MD, Richard A. Larson, MD, Albert Hoenekopp, MD, Neil J. Gallagher, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Clarisse Lobo, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 114.

https://doi.org/10.1182/blood.V118.21.114.114

Published: 2011

Journal Articles

Hydroxyurea Therapy Reduces Mortality Among Children with Sickle Cell Disease

Clarisse Lobo, MD, Jane S Hankins, MD, MS, Patricia Moura, MD, Jorge Cunha Pinto, MD

Blood (2010) 116 (21): 843.

https://doi.org/10.1182/blood.V116.21.843.843

Published: 2010

Journal Articles

Comparasion Between Nilotinib and Dasatinib as Second-Line Therapy for Patients with Chronic Myeloid Leukemia: A Single Center Retrospective Study.

Clarisse Lobo, MD, Carla Boquimpani, Tania Silva Madeira, Patricia Wendling, Claudia Maximo, Carlos Bernardo Lima, Elias Atta, Renata DE SOUZA Cravo

Blood (2010) 116 (21): 3440.

https://doi.org/10.1182/blood.V116.21.3440.3440

Published: 2010

Journal Articles

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, MD, Philipp D. le Coutre, MD, Josy Reiffers, Ricardo Pasquini, MD, Clarisse Lobo, MD, Richard E. Clark, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Ariful Haque, Richard A. Larson, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 207.

https://doi.org/10.1182/blood.V116.21.207.207

Published: 2010

Journal Articles

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Surapol Issaragrisil, MD, FRCP, FACP, FRCPA, FRCPath, Philipp D. le Coutre, MD, Josy Reiffers, MD, Clarisse Lobo, MD, Ricardo Pasquini, MD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Mei Dong, MD, MS, Ariful Haque, MS, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2009) 114 (22): LBA-1.

https://doi.org/10.1182/blood.V114.22.LBA-1.LBA-1

Published: 2009

Journal Articles

Early Absolute Lymphocyte Count Recovery after Autologous Peripheral Hematopoietic Stem Cell Transplantation Depends on the Pre-Mobilization Absolute Lymphocyte Count and the Lymphocyte Dose in the Autograft.

Elias H. Atta, MD, Cláudia J.P.B. Coelho, MD, Silvia M.P. Sarcinelli, Cláudia A. Máximo, MD, Alexandre M. Azevedo, MSc, Vera L.N. Marra, MD, Clarisse Lobo, MD

Blood (2007) 110 (11): 4973.

https://doi.org/10.1182/blood.V110.11.4973.4973

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study

Initial Molecular Response At 3 Months Can Identify Three Groups Of Patients With Different Responses and Event-Free Survival At 36-Months Following Second-Generation Tyrosine Kinase Inhibitor Therapy In Imatinib-Resistant Chronic Myeloid Leukemia

Cognitive Dysfunction Occurs In Children with Sickle Cell Anemia without Cerebral Ischemic Insult or Vasculopathy

Hydroxyurea Therapy Reduces Mortality Among Children with Sickle Cell Disease

Comparasion Between Nilotinib and Dasatinib as Second-Line Therapy for Patients with Chronic Myeloid Leukemia: A Single Center Retrospective Study.

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Early Absolute Lymphocyte Count Recovery after Autologous Peripheral Hematopoietic Stem Cell Transplantation Depends on the Pre-Mobilization Absolute Lymphocyte Count and the Lymphocyte Dose in the Autograft.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only